A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.
about
HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyRapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayEvaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.Retreatment with Sofosbuvir/Ledipasvir With or Without Lead-in Interferon-β Injections in Patients Infected with Genotype 1b HCV after Unsuccessful Daclatasvir/Asunaprevir Therapy.A comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b."Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions.Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b.Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
P2860
Q26782405-5E03A570-D411-4E9D-9BF6-DFABCA04DEEEQ28548426-78B56C34-6634-4E37-BFC6-D6349CADDB08Q36148043-2D2CD849-B3B9-40F8-8E51-B74BA5C4150DQ38755098-C83CBD49-BE47-4BB8-985A-F4EA7311A046Q38904167-E5B7AF2D-9021-421C-B07B-6857B5CCC00EQ40051404-6E7C38C0-2407-4CED-AD50-015288AD087DQ40228836-4C8D4F7C-5092-4379-95EC-4DF2917E6294Q40317327-BB41E741-C6F6-488E-8CA4-2958B1C37A5BQ40340001-0EAC7C83-1C4D-43B8-9962-9AA510D50C11Q40375437-33DECA89-D463-4D57-95E9-EA054F48F3DDQ40473780-8F29BD76-98FA-4B53-A774-EF168A0573A4Q40473920-6838843A-3A4A-446E-A3A7-D769BECF98FAQ40631323-4F7737F1-676C-485C-868E-8D1B759F3ECAQ40688823-D8559071-4E12-4A08-BBE8-222C02971B97Q40791170-ADE8C720-9FBC-4C92-A8A0-1910FEACC835Q40793177-10D89D8F-F72B-4148-86C6-629C1F217787Q41070380-E66335B8-49A7-4F6A-9501-9B5B484BD5ECQ41294797-9283F18A-B258-4DF7-B41C-EBF59914DFFBQ41690587-DF1E303B-379D-4EED-A069-697F114C2F61Q45325196-DD61EC4B-2F37-4E9C-9045-E2B746184BBAQ45325544-39D57A5B-46E3-4F1D-9062-BEA57FC994DCQ45327178-59CD37DE-0ABD-43F5-AF3B-B0F42263CBB2Q50045992-08805B47-56D0-4A75-9857-AD7B5F02D965Q53694789-EA918E38-3D21-46ED-AF63-9B1DF68DDE85Q55303958-4D81777A-F5A7-4BF9-897E-9016513A0E50
P2860
A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A novel simple assay system to ...... therapy with NS5A inhibitors.
@ast
A novel simple assay system to ...... therapy with NS5A inhibitors.
@en
A novel simple assay system to ...... therapy with NS5A inhibitors.
@nl
type
label
A novel simple assay system to ...... therapy with NS5A inhibitors.
@ast
A novel simple assay system to ...... therapy with NS5A inhibitors.
@en
A novel simple assay system to ...... therapy with NS5A inhibitors.
@nl
prefLabel
A novel simple assay system to ...... therapy with NS5A inhibitors.
@ast
A novel simple assay system to ...... therapy with NS5A inhibitors.
@en
A novel simple assay system to ...... therapy with NS5A inhibitors.
@nl
P2093
P2860
P1433
P1476
A novel simple assay system to ...... therapy with NS5A inhibitors.
@en
P2093
Jun-ichi Kouyama
Kayoko Naiki
Satoshi Mochida
P2860
P304
P356
10.1371/JOURNAL.PONE.0112647
P407
P577
2014-11-14T00:00:00Z